Sarepta Gene Therapy Trials

News

Sarepta Will Resume Gene Therapy Shipments

FDA Says Sarepta Can Resume Gene Therapy in Some Patients

In a major win for Sarepta Therapeutics Inc., US regulators are recommending that patients who can walk be allowed to take its gene therapy Elevidys again.

InvestorsHub on MSN · 8d

Sarepta Shares Drop as FDA Suspends Gene Therapy Trials for Muscular Dystrophy

Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug Administration (FDA) has imposed a clinical hold on several of its gene therapy programs targeting limb girdle muscular dystrophy (LGMD).

Associated Press News on MSN · 10d

Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene therapy.

Fierce Biotech8d

Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy

The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb-girdle ...

MarketWatch1y

Pfizer’s gene-therapy trial failure boosts Sarepta’s stock

Shares of Sarepta Therapeutics Inc. SRPT gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial. Pfizer Inc. said late Wednesday that ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

News

Sarepta Will Resume Gene Therapy Shipments

Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy

Pfizer’s gene-therapy trial failure boosts Sarepta’s stock

Trending now